Literature summary for 3.4.21.47 extracted from

Fridkis-Hareli, M.; Storek, M.; Mazsaroff, I.; Risitano, A.M.; Lundberg, A.S.; Horvath, C.J.; Holers, V.M.
Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases (2011), Blood, 118, 4705-4713.

Search for more literature for 3.4.21.47

Inhibitors

Inhibitors	Comment	Organism	Structure
TT30	therapeutic fusion protein linking the human complement receptor type 2 C3 fragment-binding domain with the CAP inhibitory domain of human factor H. TT30 efficiently blocks ex vivo CAP-dependent accumulation of C3-fragment on activated surfaces, membrane attack complex formation and hemolysis of red blood cells, without interference of C3 activation or membrane attack complex formation	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)